F. David Tingley - Concepedia

Concepedia

Author

F. David Tingley

Pfizer (United States)

Also Known As

F D Tingley, F. D. TINGLEY, F. David Tingley, F. David Tingley,, F. David Tingley, III, F.D. Tingley, Francis D. Tingley, Francis David Tingley

28

Publications

2.8K

Citations

17

H-Index

49

Concepts

All Affiliations

Pfizer (United States)

FD

About

F. David Tingley is an author at Pfizer (United States) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	15	1.3K
2	Natural Sciences	3	3	99
3	Public Health	3	3	672
4	Social Sciences	3	3	449
5	Health Sciences	1	1	32

F. David Tingley

×

21

Publications

2.8K

Citations

17

H-Index

	Year	Citations
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation Jotham W. Coe, Paige R. Brooks, Michael G. Vetelino, Journal of Medicinal Chemistry	2005	929
Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid Hans Rollema, Leslie K. Chambers, J.W. Coe, Neuropharmacology Tobacco CessationMolecular PharmacologyTobacco ControlMedicineNicotine	2006	532
CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. David W. Schulz, Robert S. Mansbach, Jeffrey Sprouse, Proceedings of the National Academy of Sciences Social SciencesMolecular PharmacologyCrf ReceptorsNeuroimmunologyNeurochemistry	1996	378
Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia C J Schmidt, Douglas S. Chapin, J. Cianfrogna, Journal of Pharmacology and Experimental Therapeutics	2008	284
Phosphodiesterase 9A Regulates Central cGMP and Modulates Responses to Cholinergic and Monoaminergic Perturbation In Vivo Robin J. Kleiman, Douglas S. Chapin, Curt Christoffersen, Journal of Pharmacology and Experimental Therapeutics	2012	79
3,5-Bicyclic aryl piperidines: A novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation Jotham W. Coe, Paige R. Brooks, Michael Wirtz, Bioorganic & Medicinal Chemistry Letters Tobacco CessationTobacco ControlMolecular PharmacologyMedicineNicotine	2005	73
2-Aryloxy-4-alkylaminopyridines: Discovery of Novel Corticotropin-Releasing Factor 1 Antagonists Yuhpyng L. Chen, R. Scott Obach, John P. Braselton, Journal of Medicinal Chemistry	2008	69
In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (−)-cytisine Jotham W. Coe, Michael G. Vetelino, Crystal G. Bashore, Bioorganic & Medicinal Chemistry Letters Tobacco CessationTobacco ControlMolecular PharmacologyBiochemistryTobacco Use	2005	67
Synthesis and SAR of 2-Aryloxy-4-alkoxy-pyridines as Potent Orally Active Corticotropin-Releasing Factor 1 Receptor Antagonists Yuhpyng L. Chen, John P. Braselton, James T. Forman, Journal of Medicinal Chemistry Medicinal ChemistryPharmaceutical ScienceBiochemistryMedicineNatural Sciences	2008	48
Modulation of NMDA receptor function by inhibition of d-amino acid oxidase in rodent brain Christine A. Strick, Cheryl Li, Liam Scott, Neuropharmacology Nmda Receptor FunctionNeuropeptidesBiochemistryNeurophysiologyRodent Brain	2011	40

Page 1